Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder

BJU International

Volumn 100, Issue 3, 2007, Pages 579-587

  Yamaguchi, Osamu ^a   Marui, Eiji ^b   Kakizaki, Hidehiro ^c   Itoh, Naoki ^d   Yokota, Takashi ^a   Okada, Hiroshi ^e   Ishizuka, Osamu ^f   Ozono, Seiichiro ^g   Gotoh, Momokazu ^h   Sugiyama, Takahide ⁱ   Seki, Narihito ^j   Yoshida, Masaki ^k  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ Fujii Clinic   (Japan)

^j KYUSHU UNIVERSITY   (Japan)

^k KUMAMOTO UNIVERSITY   (Japan)

more..

Author keywords

Efficacy; Overactive bladder; Propiverine hydrochloride; Quality of life; Solifenacin succinate; Tolerability

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; PROPIVERINE; SOLIFENACIN;

ADULT; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURIA; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; URGE INCONTINENCE; URINE INCONTINENCE; URINE VOLUME; XEROSTOMIA;

ADULT; AGED; BENZILATES; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; QUINUCLIDINES; SEVERITY OF ILLNESS INDEX; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URODYNAMICS; XEROSTOMIA;

EID: 34547628682     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07031.x     Document Type: Article

References (37)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 78
2. Wein A. Definition and epidemiology of overactive bladder. Urology 2002 60 (Suppl. 5A 7 12
3. MacDiarmid S, Rosenberg M. Overactive bladder in women. symptom impact and treatment expectations. Curr Med Res Opin 2005 21 : 1413 21
4. Castro D, Espuna M, Prieto M, Badia X. Prevalence of overactive bladder in Spain: a population-based study. Arch Esp Urol 2005 58 : 131 8
5. Hampel C, Gillitzer R, Pahernik S, Hohenfellner M, Thuroff JW. Epidemiology and etiology of overactive bladder. Urologe A 2003 42 : 776 86
6. Temml C, Heidler S, Ponholzer A, Madersbacher S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol 2005 48 : 622 7
7. Homma Y, Yamaguchi O, Hayashi K. (Neurogenic Bladder Society Committee) An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 2005 96 : 1314 8
8. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 6
9. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 36
10. Abrams P. Describing bladder storage function with overactive bladder syndrome and detrusor overactivity. Urology 2003 62 (Suppl. 2 28 37
11. Madersbacher H, Murtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 2001 19 : 324 35
12. Wuest M, Hecht J, Christ T et al. Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol 2005 145 : 608 19
13. Suzuki M, Ohtake A, Yoshino T et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. Eur J Pharmacol 2005 512 : 61 6
14. Ohtake A, Ukai M, Hatanaka T et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004 492 : 243 50
15. Ikeda K, Kobayashi S, Suzuki M et al. M (3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002 366 : 97 103
16. Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci 2004 74 : 843 53
17. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004 93 : 303 10
18. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004 93 : 71 7
19. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo-controlled trial of once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004 172 : 1919 24
20. Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR Trial. Eur Urol 2005 48 : 464 70
21. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997 104 : 1374 9
22. Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005 95 : 335 40
23. Brown JS, McNaughton KS, Wyman JF et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology 2003 61 : 802 9
24. Gittelman M. Solifenacin succinate 10 mg once daily significantly improves symptoms of overactive bladder. AUA Western Congress 78th Meeting 2003
25. Gittelman M. The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study. Int J Gynecol Obstet 2003 83 (Suppl. 3 94, Abstract TP76
26. Chapple C, Cardozo L, Steers W, Govier F. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006 60 : 959 66
27. Hunskaar S. Epidemiology of nocturia. BJU Int 2005 96 (Suppl. 1 4 7
28. Homma Y. Classification of nocturia in the adult and elderly patient: a review of clinical criteria and selected literature. BJU Int 2005 96 (Suppl. 1 8 14
29. Ali A, Snape J. Nocturia in older people. a review of causes, consequences, assessment and management. Int J Clin Pract 2004 58 : 366 73
30. Van Kerrebroeck P, Abrams P, Chaikin D et al. The standardization of terminology in nocturia: report from the Standardization Subcommittee of the International Continence Society. BJU Int 2002 90 (Suppl. 3 11 5
31. Michel MC, de la Rosette JJ. Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int 2005 96 (Suppl. 1 37 42
32. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000 55 (Suppl. 33 46
33. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997 104 : 988 93
34. Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995 6 : 243 62
35. Crandall C. Tolterodine: a clinical review. J Womens Health Gend Based Med 2001 10 : 735 43
36. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006 175 : 999 1004
37. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005 95 : 81 5